EUCTR2006-002830-38-GR进行中（未招募）不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age ³ 18 years old.
- •2.The subject has pathologically (histologically and/or cytologically) documented NSCLC.
- •3.The subject has locally advanced (Stage III) NSCLC not amenable to curative surgery or radiotherapy or metastatic (Stage IV) NSCLC.
- •4.The subject has received only one prior anti-tumor treatment regimen in the advanced (Stage III non-curable disease or metastatic Stage IV) setting (i.e., study participation must be second line therapy in the advanced setting).
- •5.The subject may have received one additional anti-tumor treatment regimen in the neo-adjuvant or adjuvant setting.
- •6.The subject has experienced progressive disease either during or following the previous anti-tumor treatment regimen (Requirement for Phase 2 only).
- •7.The subject exhibits the presence of measurable disease by RECIST criteria (Requirement for Phase 2 only).
- •8.Subjects with brain metastases must have had clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 30 days of stable neurologic function and no evidence of CNS disease progression.
- •(Subjects with symptoms of CNS metastasis at Screening must have computed tomography [CT] or magnetic resonance imaging [MRI] scans of the brain prior to study entry that demonstrate no evidence of disease.)
- •9.The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
- •10.All anti-tumor therapy has been discontinued at least 3 weeks prior to study start administration.
- •11.All adverse events from prior anti-tumor treatment are resolved or stable.
- •12.Adequate hematologic, renal and hepatic function
- •13.Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a serum pregnancy test.
- •14.All female subjects not surgically sterile or postmenopausal (for at least 1 year) and non-vasectomized male subjects must practice at least one of the listed methods of birth control.
- •15.The subject's life expectancy is ³ 3 months.
- •16.The subject is amenable to completing the Quality of Life (QoL) questionnaire (Requirement for Phase 2 only).
- •17.Subject has voluntarily signed and dated an informed consent form, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any study specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The subject has greater than Grade 1 NCI CTCAE (Version 3.07) neurology category findings (e.g., paresthesia, deep tendon reflexes, or weakness that is subjective and/or does not interfere with function).
- •2.The subject has a documented allergy to sulfa medications.
- •3.The subject has previously received ABT-751 or pemetrexed.
- •4.The subject has received more than one investigational agent for NSCLC as a single agent or part of a previous regimen. (An investigational agent is any drug not currently approved for use in humans. Please contact the Abbott medical monitor with questions regarding investigational agents.)
- •5.The subject exhibits significant weight loss (³ 10%) during the 6 weeks before study entry.
- •6.The subject has glucose-6-phosphate dehydrogenase deficiency and/or porphyria.
- •7.The subject has a significant history of cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic, or hepatic disease that would adversely affect his/her participating in this study. Questions regarding inclusion of individual subjects should be directed to the Abbott Medical Monitor.
- •8.The subject has a current history of a Class 3-4 cardiovascular disability status in accordance with the New York Heart Association Functional Classification.
- •?Class 3 is defined as marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes fatigue or dyspnea.
- •?Class 4 is defined as being unable to carry on any physical activity without symptoms and symptoms are present even at rest. Also, if any physical activity is undertaken, symptoms are increased.
- •9.A female subject is pregnant or breastfeeding.
- •10.The subject has previous or current malignancies at other sites, with the exception of:
- •?adequately treated in situ carcinoma of the cervix uteri;
- •?basal or squamous cell carcinoma of the skin;
- •?previous nonpulmonary malignancy (e.g., localized prostate cancer) confined and surgically resected, treated with chemotherapy or radiation therapy, and is considered cured by the investigator.
研究者
相似试验
进行中（未招募）
不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2006-002830-38-CZAbbott GmbH & Co. KG180
进行中（未招募）
不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerAdvanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following one or more chemotherapy regimens.MedDRA version: 8.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-002830-38-DEAbbott GmbH & Co. KG180
进行中（未招募）
不适用
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2006-002830-38-NLAbbott GmbH & Co. KG180
招募中
2 期
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer2023-508256-19-00Janssen Cilag International38
已完成
2 期
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung CancerNL-OMON30442Abbott20